Life Sciences
The strategy is focused on creating and building life science companies addressing significant unmet needs for patients with limited or no treatment options.
The senior members of the team have a 20+ year track record of building successful life science companies relevant to this strategy. The team has deep operational experience in drug discovery and development.
Regions
- Western Europe
- United States
Portfolio companies and realisations
The Life Sciences strategy aims to build a portfolio of c.12 to 15 preclinical and clinical stage growth opportunities with equity investments of $10-50m per company.
Life Sciences in ICG Client Lounge
Find out more about this strategy within our digital hub for clients and consultants.
Explore
Life Sciences events calendar
(Year)
Date
Event
Website
2025
15 May 2025
Head of Life Sciences Dr Allan Marchington takes part in discussion entitled UK Venture Capital for the LGPS – a New Frontier, at Room151's LGPS North 2025, in Manchester15 May 2025
2025
13 May 2025
Head of Life Sciences Dr Allan Marchington speaks at Bio€quity Europe 2025 in Bruges13 May 2025
2025
03 Apr 2025
Head of Life Sciences Dr Allan Marchington participates in Trends in Life Science Investments panel discussion at Anglo Nordic's Life Sciences Conference XXI conference in London03 Apr 2025
2025
17 Mar 2025
ICG Life Sciences team attends BIO-Europe Spring in Milan (to 19 Mar)17 Mar 2025
Meet the Life Sciences team
Related people
Explore our portfolio companies
CuraSen Therapeutics
CuraSen Therapeutics is a clinical-stage company developing small molecule therapies to treat neurodegenerative disease.
Grey Wolf Therapeutics
Grey Wolf Therapeutics is a clinical-stage, drug discovery and development biotechnology company spearheading a new therapeutic approach
Wugen Inc
Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.
Successful realisations
Amolyt Pharma
Amolyt Pharma is a clinical stage biotechnology company working to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
Get in touch
To find out more about our flexible and sustainable solutions for both providers and users of capital, please contact us.
Contact us
